Briacell Showcases Positive ASCO 2025 Data
BriaCell Therapeutics Corp. announced positive Phase 2 clinical trial data for its Bria-IMT™ immunotherapy in metastatic breast cancer, demonstrating...
eClinical Tech News
Iovance Announces Five-Year Amtagvi® Results in Melanoma Patients at ASCO
Iovance Biotherapeutics announced five-year follow-up data from the Phase 2 C-144-01 trial of its tumor-infiltrating lymphocyte (TIL) therapy, Amtagvi...
Petosemtamab Plus Pembro Show Robust Efficacy in 1L PD-L1+ R/M HNSCC
Merus N.V. announced interim phase 2 trial data for petosemtamab combined with pembrolizumab in treating head and neck squamous...
ImCheck AML Therapy Shows High Remission at ASCO 2025
ImCheck Therapeutics announced positive interim results from its Phase I/II EVICTION study of ICT01, a novel γ9δ2 T-cell activator,...
Taiho Pharma Zipalertinib Shows Promise in Pivotal Phase 2b Trial
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology announced positive Phase 2b results from the REZILIENT1 trial of zipalertinib, an...
Adagene Announces Updated Data from Phase 1b/2 Study of Muza in Colorectal Cancer at ASCO
Adagene Inc. released updated Phase 1b/2 clinical trial data for ADG126, a novel anti-CTLA-4 antibody, combined with pembrolizumab in...
Candel Therapeutics’ Positive Phase 3 Results in Prostate Cancer
Candel Therapeutics announced positive Phase 3 trial results for aglatimagene besadenovec (CAN-2409) combined with valacyclovir in patients with intermediate-to-high-risk...
ORUKA Therapeutics Doses First Participants in Phase 1 Trial of Anti-IL-17A/F Antibody
Oruka Therapeutics has started dosing healthy volunteers in a Phase 1 clinical trial for ORKA-002, a novel subcutaneous monoclonal...
Cingulate ADHD Study: CTX-1301 Efficacy Results Announced
Cingulate Inc. announced positive efficacy results from a Phase 3 clinical trial of CTx-1301, its dexmethylphenidate-based ADHD treatment, in...
Silexion Shows Promising Preclinical Results in Cancer Studies
Silexion Therapeutics (NASDAQ: SLXN) has completed preclinical studies of its RNAi therapeutic candidate, SIL204, in colorectal, lung, and pancreatic...